Lonza Group AG | Income Statement

Fiscal year is January-December. All values CHF Millions.
2013
2014
2015
2016
2017
Sales/Revenue
3,584
3,640
3,803
4,132
5,105
Cost of Goods Sold (COGS) incl. D&A
2,580
2,506
2,612
2,704
3,330
Gross Income
1,004
1,134
1,191
1,428
1,775
SG&A Expense
573
665
670
833
1,003
EBIT
422
455
505
546
744
Unusual Expense
109
147
64
67
25
Non Operating Income/Expense
77
130
15
22
18
Interest Expense
108
84
87
85
133
Pretax Income
134
363
343
374
578
Income Tax
18
42
64
72
150
Equity in Affiliates
29
84
2
1
-
Consolidated Net Income
87
237
277
301
728
Net Income
87
237
277
301
726
Net Income After Extraordinaries
87
237
277
301
726
Net Income Available to Common
87
237
277
301
726
EPS (Basic)
1.55
4.22
4.91
5.31
10.70
Basic Shares Outstanding
56
56
56
57
68
EPS (Diluted)
1.55
4.21
4.87
5.27
10.60
Diluted Shares Outstanding
56
56
57
57
68
EBITDA
731
754
805
853
1,155
Other Operating Expense
9
14
16
49
28
Non-Operating Interest Income
6
9
4
2
10
Minority Interest Expense
-
-
-
-
2

About Lonza Group

View Profile
Address
Muenchensteinerstrasse 38
Basel Basel-Stadt (Basle Town) 4002
Switzerland
Employees -
Website http://www.lonza.com
Updated 09/14/2018
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the Pharma&Biotech and Specialty Ingredients segemnts. The Pharma&Biotech segment deals with the supply of pharmaceutical ingredients and biopharmaceuticals as well as research and testing products and services.